- Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Gross, N.D., Bauman, J.E., Gooding, W.E., Denq, W., Thomas, S.M., Wang, L., Chiosea, S., Hood, B.L., Flint, M.S., Sun, M., Conrads, T.P., Ferris, R.L., Johnson, J.T., Kim, S., Argiris, A., Wirth, L., Nikiforova, M.N., Siegfried, J.M., Grandis, J.R. Clin. Cancer Res. (2014)